

Newsletter July - Sept 2020

CEO's greetings

Hei kaikki! This is our first newsletter since I've joined the company on July 1st, 2020. It has been an excellent and energising start getting up to speed with our company story with the aid of our very skilled and committed team. Our story is a brilliant one, with superb science and promising data and I look forward to sharing more as we progress. It has been a busy time for the company. We issued our half yearly report, announced promising topline data on our CDNF program, presenting at several congresses, interviewed with Finnish and Swedish financial news outlets, met with some of our key shareholders, and our lead candidate, Lymfactin[®], appeared as the cover title for the top tier 'Journal Of Plastic, Reconstructive and Aesthetic Surgery'!

It is also important to note that despite Covid19 challenges, we do not expect any material effect or delays to our programs – this is a true testament to the hard work and expertise of the entire Herantis team and our collaborators. Pekka Simula, my predecessor, continues to be involved in the company as an advisor, and it has been great working together in ensuring a smooth and productive transition. The entire team has been very welcoming and supportive with my onboarding, thank you! I am excited about the future of Herantis, and very much look forward to building on the current foundation as we enter the next chapter of the company's compelling journey.

CLINICAL PROGRAMS

- **CDNF & Parkinson's disease:** 12-month data from our CDNF First-in-Human Phase I study was announced as scheduled. A webinar will be held on 15th September to discuss the data. In summary CDNF treatment was confirmed as safe in humans, the main objective of the study. In addition, we were encouraged to observe potential signals of efficacy in some patients incl. motor improvements as well as improved dopamine signals in the brain.
- **Lymfactin[®] & Lymphedema:** Phase 2 study AdeLE continues on schedule, and 12-month results are expected in Q1/21 after a 12-month blinded follow-up. 24-month data from the original Phase I study is also expected in the near term.
- **xCDNF & Parkinsons:** molecular optimization continues at pace for xCDNF, our next generation treatment for Parkinson's. Using the smallest and most powerful parts of the original CDNF molecule, the intention is that xCDNF will be able to reach the brain without the need for surgery (as is currently needed for CDNF). We hope to select the final xCDNF molecule in H1/2021.

PLANNED ACTIVITIES

- **Company webinar:** CDNF Phase I-II Study Met Primary Endpoints of Safety and Tolerability at 12 months on Sep 15 (see herantis.com for details)
- **MDS Virtual Congress**, 12-16 September, where two presentations on the CDNF clinical trial will be presented.
- **Red Eye** Live-broadcasted CNS-event on October 15
- **Seminar** "World's first clinical trial with CDNF: Aiming for a breakthrough in Parkinson's" webcast 18 Nov 2020

Herantis Highlight of The Month



Herantis' treatment for Lymphedema appears on front cover of JPRAS

Keep up-to-date on Herantis:



Contact us



@Herantis Pharma



Subscribe

Highlights from team

- The first week of September was a big one for Herantis. We presented at four important events:
 - o LSX Nordic Congress in Stockholm
 - o Pareto Securities Healthcare Congress in Stockholm
 - o Sijoitus Summit in Helsinki (see www.sijoitussummit.fi)
 - o Danske Bank Small & Mid Cap Day in Helsinki
- Herantis were very pleased to collaborate with the lymphedema patient advocacy group LE&RN and conduct a patient survey with 368 lymphedema patients residing mainly in the US in order to collect more information about the disease, symptoms, quality of life and willingness to participate in future clinical studies.

Topics of interest

- Lymfactin[®] was selected to be on the cover of the acclaimed JPRAS journal (insert pic). This refers to the first scientific article published on our Lymfactin[®] clinical study! Hartiala et al: Phase 1 LymfactinR Study: Short-term Safety of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema. Journal of Plastic, Reconstructive & Aesthetic Surgery.
- We appointed a new investor relations team as of 1 September 2020. JG-IR is a Swedish based financial and healthcare communications firm that will support Herantis to help establish best-in-class investor relations and expand our exposure with key audiences in Nordic and global capital markets.

Herantis in the news

- Interviews with Herantis management were held with Direkt financial news agency in Sweden, Inderes financial news agency in Finland., and Sijoitus Summit in Helsinki, See <https://herantis.com> or
 - o https://www.youtube.com/watch?v=IGr-mqFc8_w and
 - o <https://www.inderes.fi/fi/videoot/herantis-pharma-h120-kohti-seuraava-vaihetta-eng>
 - o <https://www.sijoitusareena.fi/areena/herantis-pharma/>